Oral administration of lysophosphatidic acid (LPA), a critical intercellular lipid mediator, exerts wound healing and antiulcer effects on gastrointestinal system. To evaluate effects of food-derived LPA on body homeostasis, we measured LPA levels by liquid chromatography-tandem mass spectrometry in chows, feces, plasma, liver, and visceral fat of mice fed a normal or high-fat chow supplemented with or without LPArich soybean phospholipids for 30 days. Reductions in daily body weight gains and visceral fat mass were mainly related to lower chow intake by mice fed the LPA-rich high-fat chow, whereas reduced body weight gains and fat mass were mainly related to decreased intestinal triacylglycerol absorption in mice fed LPA-rich chow. Our results showed no significant increase in plasma, liver, or adipose LPA levels, even if a quite high LPA concentration (2.0%) in chows was ingested daily, suggesting limited effects of food-derived LPA on the lumen side of the digestive tract.
Introduction
Energy homeostasis comprises complex processes affected by both central and peripheral signal-transduction pathways. A large proportion of dietary phospholipids are decomposed to their corresponding lysophospholipids, which are able to interact with other lipid components in mammalian digestive tracts [1] . For example, phosphatidylcholines inhibit intestinal absorption of micellar forms of cholesterol and fatty acids in the rat jejunum sac in vitro [2] , whereas lysophosphatidylcholine (LPC), its major metabolite in the sac, enhanced the absorption of fatty acids but not cholesterol [3] . In mammalian digestive tracts, food-derived lysophospholipids were found to exert physiological actions other than those on digestive uptake of neutral lipids in the digestion system before its absorption [1] . Some proportions of dietary lysophospholipids may be taken intact into the intestinal cells, and these very small proportions are subsequently transported by the lymph or blood without hydrolytic degradation or condensation with the appropriate fatty acylcoenzyme A, exerting beneficial or adverse effects on organs other than the intestines. The central member of the lysophospholipid mediator family is lysophosphatidic acid (LPA), which was originally identified as a smooth muscle-stimulating substance in lipid extracts from horse, rabbit, and guinea-pig brain [4] and as a vasoactive substance in soybean lecithin [5] . Although many studies have been done on the physiological and pathophysiological roles of LPA in the blood and tissues of mammals [6, 7] , there are a limited number of reports that LPA exerts a physiological action on the lumen side of the digestive system [1] . Sturm et al. reported that daily rectal injection of LPA for 7 days to rats had a beneficial wound-repairing effect [8] . In addition, rectal administration of LPA was found to inhibit chloride secretion by regulation of cystic fibroblast transmembrane conductance [9] . Radiation injury of mouse intestinal mucosa was found to be rescued by prior oral administration of a synthetic LPA, octadecenyl-thiophosphate [10] . Our group previously reported that prior intragastric administration of LPA to rats under water immersion/restriction stress and mice undergoing aspirin treatment reduced the gastric ulcer scores in both animals [11, 12] .
A recent report showed that an increased concentration of dietary fish oil resulted in an increased serum concentration of docosahexaenoyl-LPC with decreased concentrations with 2-arachidonoyl-LPC and 1, 2-arachidonoyl-glycerophosphoethanolamine in beagles [13] . In this study using mice, we measured levels of LPA in blood plasma, liver, and visceral adipose tissue by liquid chromatography-tandem mass spectrometry (LC-MS/MS), to determine how much dietary intake of LPA is needed to significantly elevate its circulating and peripheral levels. LPA may affect the body homeostasis because LPA produced by the lysophospholipase D activity of autotaxin in mice affects the visceral fat mass [14] . To attain further fundamental data in order to develop LPA-rich foods as an antiulcer or oral care supplement for humans, we determined what portions of LPA in chows are absorbed by mouse intestinal epithelium by measuring LPA levels in the control and LPA-supplemented chows and feces of mice that ate these chows for 30 days. In other words, we attempted to estimate what portions of LPA in the chows reached by evading intestinal absorption. Due to the need for a large amount of LPA for supplementation to the standard chows for mice during a prolonged period, we used LPA from a natural source. In our previous work, LPA purified from soybean lecithin at about 0.5% yield was found to exert vasoactive effects when intravenously injected in experimental animals [5] . Therefore, we used an LPA-rich soybean phospholipid mixture (SPL) as a supplement to standard chows with a normal or high-fat content.
Materials and methods

Materials
Milk casein, α-corn starch, sucrose, cellulose powder, lard, AIN76 vitamin mixture, and AIN76 mineral mixture were obtained from Oriental Yeast (Tokyo, Japan). Ammonium formate, choline bitartrate, DL-methionine, and soybean oil were purchased from Wako Pure Chemical Industries (Osaka, Japan). Acetonitrile, methanol, and distilled water for LC-MS/MS were obtained from Kanto Chemicals (Tokyo, Japan). Soybean oil was purchased from and SPL were products of Nagase ChemteX Corporation (Fukuchiyama, Japan). SPL (21.1-37.1 mg) was dissolved in a mixture of chloroform-methanol (2:1, v/v), and phospholipids in SPL were quantified by high-performance liquid chromatography (HPLC) as described previously [15] . 1-Heptadecanoyl (17:0)-LPC and 1-heptadecenoyl (17:1)-lysophosphatidylinositol (LPI) were purchased from Avanti Polar Lipids (Alabaster, AL). Both 17:0-LPA and 17:0-lysophosphatidylethanolamine (LPE) were prepared by the hydrolysis and transphosphatidylation of 17:0-LPC with Streptomyces chromofuscus and Actinomodula sp. phospholipase D, respectively [16, 17] . , DL-methionine (3.00 g/kg), and choline bitartrate (2.00 g/ kg). High-Fat chow was supplemented with SPL (about 46%) at a final percentage of 1, 2, or 5% (w/w) with a concomitant reduction in the soybean oil concentration from 70.0 to 61.6, 53.2, or 28.0 g/kg, respectively. The total energy of Normal chow was the same with that of High-Fat chow. The energy percentages of protein, carbohydrates, and fat were 20.5, 63.6, and 15.9% for the Normal chow, respectively, and 20.5, 34.5, and 45.0% for High-Fat chow, respectively. The concentrations of LPA and other lysophospholipids in the chows were determined by LC-MS/MS after lipid extraction, essentially as shown previously [17] .
Chows
Animals
Experiments using male mice were approved by the Tokushima University Animal Care and Use Committees, and followed the National Institutes of Health Guide for the Care and Use of Laboratory Animals. Five-week old male C57BL/6J mice were purchased from Charles River Laboratories Japan (Yokohama, Japan). Six groups of four mice per cage received Normal chow supplemented with SPL (2 or 5%) or with High-Fat chow supplemented with SPL (1, 2, or 5%). Eight mice (four each in two cages) were given High-Fat chow containing 5% SPL. Mice were maintained on a 12:12 light-dark cycle in a wire cage and fed ad libitum High-Fat chow as a paste or Normal chow as pellets for the first week, and then High-Fat chow with SPL (0, 1, 2, or 5%) or Normal chow with SPL (0, 2, or 5%) from the second week for 30 days, and with free access to drinking water during the experiment.
Measurements of body weight/food intake and collections of feces, blood, and organs
Every 3 days, the average body weight of eight mice in two cages (4 mice each) of mice fed High-Fat chow with 5% SPL or four mice in a cage for the other six groups, but not the body weight of individual animal, was recorded in the evening. The food intake per day for each cage was measured on the first, fourth, seventh, 10th, 13th, 16th,19th, 22nd, 28th and 30th days by weighing the supplied chow and weighing the left-over chow prior to replacing it with fresh chow, and their averages and standard errors were calculated. Feces from these groups were collected twice in 30 days for measurement of lysophospholipid levels by LC-MS/MS. Portions of fecal samples were dried at 110 C for 12 h to measure their dry weight for normalization of data obtained by LC-MS/MS. At 30 days all mice were fasted for 18 h and sacrificed under anesthesia with ethyl ether. Blood was collected from the abdominal artery into a plastic tube containing 1 mg disodium ethylenediamine-N, N, N 0 , N 0 -tetra-acetic acid. The anti-coagulated blood was centrifuged at 1000 x g for 10 min to prepare plasma samples at 4 C. Liver, kidneys, epididymis fat, renal visceral fat, and visceral fat from intestinal mesenteric vessels were collected on ice. Immediately after weighing, these tissues were stored at −80 C.
Lipid extraction
Lipids were extracted from plasma (0.1-0.2 mL), liver (0.2-0.5 g), fat (0.2-0.3 g), and feces (0.15-0.2 g) essentially by a modified method of Bligh and Dyer [17] . The samples of liver, fats and feces were suspended in 0.8 mL of double-distilled water containing 5% potassium chloride and homogenized after addition of 3 mL of chloroform-methanol mixture (1:2, v/v) under vigorous stirring. Mouse plasma (0.1-0.2 mL) was diluted with double-distilled water containing 5% KCl to 0.8 mL, and mixed with 3 mL of chloroform-methanol mixture (1:2, v/v). Internal standards (5 nmol 17:0-LPC, 2.5 nmol 17:0-LPE, 0.5 nmol 17:0-LPA, and 0.2 nmol 17:1-LPI) were added for LC-MS/MS, and the tissue and plasma homogenates were subjected to sonic treatment for 10 s followed by standing 4 C for 20 min. After centrifugation, the resultant aqueous layer was withdrawn, and mixed with 1 mL each of chloroform and double-distilled water. After adjusting the pH to 8-9, phase separation was performed by centrifugation, and the organic layer was withdrawn. The remaining aqueous layer was mixed with chloroform-methanol mixture (17:3, v/v) with an equal volume of the withdrawn organic layer, and the pH adjusted to 2-3 followed by centrifugation. The pooled first and second organic layers were dried separately under a stream of nitrogen gas, and the residues were stored at −80 C until use for LC-MS/MS. 
LC-MS/MS
Analysis of TG level
Triacylglycerol (TG) concentrations in liver, feces, and plasma were determined by a LaboAssay Triglyceride Kit (Wako Pure Chemical Industries) according to the manufacturer's protocols.
Cell culture
Caco-2 cells were cultured for 14 days post confluence onto polycarbonate Transwell filter inserts with 0.4 μm pores, as described previously [18] . SPL were dissolved in the culture medium in the apical or basolateral side at 100 μg/mL. Lipids were extracted from the culture media withdrawn at various incubation times, and LPAs were measured by LC-MS/MS as described above.
Statistical analysis
Statistical analysis for two groups was done using Student's ttest. The differences of average values of multiple groups were statistically analyzed by analysis of variance (ANOVA) followed by Turkey's post hoc test. P < 0.05 was considered statistically significant.
Results
Effects of SPL supplementation to chows on food intake and body weight gain
First, we examined the phospholipid class composition of the SPL used in this study by HPLC. This LPA-rich preparation from soybean lecithin was found to comprise LPA (46.2% of total weight), phosphatidic acid (5.0%), cyclic phosphatidic acid (1.3%), phosphatidylinositol (2.1%), LPI (2.9%), LPE (2.0%), phosphatidylethanolamine (2.5%), LPC (0.9%), and phosphatidylcholine (0.5%). The result shows that LPA was highly purified in SPL, accounting for about 62% of the total lipid weight of SPL and 73% of the total weight of phospholipids. Next, we Next, we quantified the concentration of total LPA in SPLsupplemented chows by HPLC. Normal chow supplemented with 2 and 5% SPL was found to contain the actual amount of LPA as mean percentage of 0.74 AE 0.27 and 1.75 AE 0.15 weight %, respectively, as the mean AE standard deviation (n = 3). Similarly, the concentrations of LPA in High-Fat chow with 1, 2, and 5% SPL were 0.39 AE 0.14, 0.74 AE 0.68, and 1.97 AE 0.36 weight %, respectively. The LPA levels of these chows without supplementation of SPL were less than the threshold of HPLC used in this study.
The average food intake of mice fed the Normal diet with 0, 2, and 5% SPL were higher than those fed the High-Fat diet with 0, 2, and 5% SPL, respectively, as shown in Fig. 2A . This may be a reason for the essentially identical daily body weight gains of mice fed High-Fat and Normal chows without SPL for 30 days (Fig. 2B and C) , despite the much higher fat concentration due to added lard in the High-Fat chow than that of Normal chow without lard. In addition, the food intake by mice fed High-Fat chow with 5% SPL was significantly lower than other groups fed High-Fat chow, whereas no significant difference among groups fed Normal chow was obtained ( Fig. 2A) . In analogy with the results on food intake, SPL supplementation at 5% to the chows resulted in lower daily body weight gains by groups fed both High-Fat and Normal chows, although the lower gain for the High-Fat-fed group was higher than that for Normal-fed groups ( Fig. 2B and C) . At 30 days, the average body weight of mice fed High-Fat and Normal chows with 5% SPL were 83.7 and 92.5% of those fed High-Fat and Norman chows without 5% SPL. Because of significant difference in the body weight gains and food intakes were observed either between both Normal with and without 5% SPL or High Fat with and without 5% SPL, we focused on these four groups in subsequent experiments.
Effects of SPL supplementation to chows on weights of heart, liver, kidney, and adipose tissue
There were no significant differences in the weight of liver, kidney, and heart among the High-Fat and Normal chow groups with and without SPL (1, 2, or 5%), respectively (Fig. 3) . Figure 4 compares the total, perirenal, epididymis, and intestinal blood-associated fat weights per 100 g body weight. There were significant differences in the total fat weight, perirenal fat weight, and epididymis fat weight among the High-Fat chowfed groups. Supplementation of 5% SPL to the chow was tended to reduce the intestinal blood-associated fat weight of Normalfed and High-Fat-fed groups, but the difference in the mean values did not reach statistical significance.
Effects of SPL supplementation to chows on TG levels in plasma, liver, and feces
We examined the effects of SPL supplementation on the plasma levels of TG. There were no significant differences in plasma TG levels among the groups fed Normal and High-Fat chows with or without 5% SPL (Fig. 5A ). As shown in Fig. 5B , no difference in the liver levels of TG in the four groups was observed. The concentration of TG in feces from groups fed Normal chow with 5% SPL was significantly higher than that fed Normal chow without 5% SPL. Similarly, the concentration of TG in feces from mice fed High-Fat chow with 5% SPL was significantly higher than that fed High-Fat chow without 5% SPL, while the fecal TG level in mice fed Normal chow with 5% SPL was higher than that in mice fed High Fat with 5% SPL (Fig. 5C). 3.4. Measurement of LPA molecular species levels in feces, liver, blood, and epididymis fat
We quantified the total and individual levels of LPA in the feces from the mice fed Normal, Normal 5% SPL, High Fat, and High Fat 5% SPL chows. There were very low total levels of LPA in groups fed Normal and High-Fat chow, whereas significantly higher level of LPA was detected in the groups fed Normal 5% SPL chows (Fig. 6A) . As expected, the predominant molecular species of LPA in the feces were 16:0, 18:0, 18:1, 18:2, and 18:3 (Fig. 6B) . Next, we measured the levels of liver LPA in mice fed Normal and High-Fat chows with and without 5% SPL, but found no significant differences in the total and individual LPA levels among the groups (Fig. 6C and D) . The most abundant molecular species of LPA was 18:0 for the group fed Normal chow with and without 5% SPL, followed by 22:6 and 16:0 in that order (Fig. 6D) . Furthermore, we quantified the plasma levels of total and individual LPAs. There were no significant differences between the four groups tested (Fig. 6E and F) . We analyzed levels of total and individual LPAs in the epididymis fat, but found no significant differences among the values of the four groups ( Fig. 6G and H) . Previously, we showed that an exogenously added fluorescent analog of LPA to apical medium, but not basolateral medium, culturing enterocyte-like differentiated Caco-2 cells in Transwell chambers was degraded into corresponding fluorescent fatty acid after incubation [18] . Figure 7 shows similar apical site-specific disappearance of various LPAs in SPL added to the differentiated Caco-2 cells in Transwell chambers. No significant amounts of LPAs were detected in the recovered cells and the medium at an opposite site (for example, apical medium in the case that SPL was added to basolateral medium). These results support that a quite high portion of food-derived LPAs in SPL were metabolized through it passing the intestinal cell layer.
Discussion
Potential mechanisms of decreased body weight and fat mass in mice fed SPL-supplemented chow
For assessment of the safety and effectiveness of dietary LPA in humans, the current study was designed to study the effects of supplementation of LPA purified from soybean lecithin at high concentrations to ordinary diets on mouse body mass, masses of major organs, and plasma/tissue LPA levels. Unexpectedly, we first found lower daily food intakes and essentially identical reductions of body weight gains of mice fed High-Fat chow compared with those of mice fed Normal chow as controls for those with SPL supplementation, although the intake of TG-rich lard by mice fed High-Fat chow (45.0% fat energy%) was about three times higher than that fed Normal chow (15.9% energy %)-fed mice. This would be mainly due to reduced food intake by mice fed the High-Fat chow. In fact, higher levels of dietary TG-derived free fatty acids and monoacylglycerols in the lumen of digestive tracts were shown to exert a higher inhibitory effect on food intake by mice via central and circulatory controls [19, 20] . Previously, one of the G protein-coupled receptor for LPA, LPA 5 (also named GPR93), was reported to be located on the apical plasma membrane of intestinal epithelial cells [21] , and responsible for activation with dietary components such as Inoue et al.
protein-derived peptides [22] . Thus, the observed inhibitory effect of supplementation of 5% SPL to High-Fat chow on the food intake found in this study might be mainly ascribed to the satietogenic effect of dietary LPA on the apical side of enteroendocrine cells that is potentially synergized with the known satietogenic effects of dietary TG-derived free fatty acids and monoacylglycerols that stimulate vagal afferents, release glucagon-like peptide-1/ peptide YY from intestinal endocrine L cells [23, 24] , and cholecystokinin from intestinal endocrine I cells [25] , and generate oleoyl-ethanolamide in intestinal cells [25] . In addition, the moderate, but significant increase in the fecal TG level of mice fed High-Fat chow with 5% SPL suggests reduced intestinal absorption of dietary TG as an additional mechanism of observed reduction in the body weight of the mice. We found that supplementation of SPL at 5% (as LPA at 2.0%), but not at 2%, to High-Fat chow reduced body weight gains of mice more severely than that the same addition to Normal chow did. The reduced body weight gain due to 5% SPL supplementation is likely to be associated with a lower mass of visceral fat in mice fed High-Fat chow than those fed Normal chow. Since the daily oral administration of high amounts of LPA in the chows for 30 days caused no significant changes in either the total and molecular species composition of plasma LPA in mice fed High-Fat chow or Normal chow in this study, LPA transported to peripheral tissues after its absorption through the intestinal epithelium is unlikely to promote the fat mass reduction through its direct action on preadipocytes and adipocytes, as described above. Thus, a major mechanism for reduced body weight gains by mice fed Normal chow with 5% SPL is assumed to be due to reduction of TG absorption by potential inhibition of secretory lipase activity toward TG in the lumen of the digestive tract either through its direct interaction with the enzyme or modification of surface properties of the substrate emulsion composed of dietary lipids and biliary phosphatidylcholines and bile acids.
4.2.
Negative impact of prolonged LPA supplementation on plasma and tissue levels of LPA LPA exerts a diverse array of physiological effects through the activation of its specific G-protein coupled receptors (LPA 1 -LPA 6 ) [7] . Because cultured gastric and intestinal epithelial cells were reported to express LPA 2 or LPA 5 on the cell membrane of the apical lumen [10, 12, 21] , both LPA in foods or LPA generated from its precursor phospholipids (phosphatidic acid and LPC) in the digestive lumen can exert their specific action on the digestive lumen [1] . The second purpose of this study was to determine whether intake of LPA-added Normal and High-Fat chows in about 1 month, affects blood and tissue levels of LPA, which are expected to affect homeostasis of mouse body and energy as a critical signal molecule. However, our results showed no significant differences in the plasma, liver and visceral fat levels of LPA between mice fed the chow with and without 5% SPL containing mainly LPA. Thus, most LPA molecules in the chows with 5% SPL might be very effectively taken and degraded in the digestive tracts of the small intestine, while a small amount of LPA was detected in the feces of mice that received 5% SPL-Normal or 5% SPL-High-Fat chows. Most of the expected degradative metabolites (free fatty acid, monoacylglycerol, glycerol-3-phosphate) in the intestine would not to be utilized to increase either circulating and liver/adipose tissue levels of the predominant LPA because there were no differences in both compositions and amounts of individual molecular species of LPAs in plasma, liver, and visceral adipose tissue despite the characteristic composition of soybean LPA which has a high percentage of 18:2 species and a moderate percentage of 18:3 LPA. Previously, our group reported that 18:3-LPA was more potent in inducing contraction of isolated guinea-pig ileum than 18:2-LPA, 18:1-LPA, and 16:0-LPA [27] . Thus, beneficial and/or harmful effects of LPA added to the chow, if they occurred, are largely exerted on the digestive lumen before its absorption, but not on peripheral tissue including the liver and adipose tissue after its absorption by the small intestine. This means that the observed beneficial effects of LPA supplementation to the chow in previous studies [8] [9] [10] [11] , are largely due to its direct effects on the apical side of gastrointestinal epithelial cell layers before its absorption. It should be mentioned, however, that feeding of a Western diet by female lipoprotein receptor-null mice on a C57BL/6 J background for 2.5 weeks increased the intestinal contents of unsaturated LPAs (18:1, 18:2, and 20:4), compared with those fed an standard chow,
FIG 6
Total and individual levels of LPA in feces (A, B), liver (C, D), plasma (E, F), and epididymis fat (G, H) of mice fed High-Fat or Normal chow with and without supplementation of 5% SPL for 30 days. Results are means AE S.E. of feces (n = 3, 4, or 8), liver (n = 3, 4, or 6), plasma (n = 3-6), and epididymis fat (n = 3).
# P < 0.05 (Student's t-test), *P < 0.05 versus Normal chow, High-Fat chow or High-Fat chow without 5%SPL.
and addition of unsaturated LPA to the chow resulted in its increased intestinal level [28] . The authors suggested that Western diet-mediated dyslipidemia (increased levels of plasma TG and total cholesterol, decreased level of high density lipoprotein-cholesterol) may be due in part to Western dietinduced LPA level in the small intestine [28] . Although orally administrated LPA was reported to exert several beneficial effects on the digestive system, caution should be directed to potential aggressive effects of the LPA-rich chow on oral, pharynx, esophagus, and gastric tumors due to its high levels in the lumen of the upper digestive tract. In fact, LPA was reported to stimulate proliferation and motility of squamous carcinoma cell lines [29] , induce proliferation of tongue, esophagus, and pharynx carcinoma cells [30] , and regulate the migration of gastric cancer cells [31] . In addition, many previous studies showed LPA-induced metastasis of mammalian colonic tumor cells in vitro and in vivo [32] [33] [34] . Our results showed that significant increases in the level of fecal LPA were observed in mice fed Normal chow supplemented with 5% SPL, indicating that the risk of LPA supplementation on promotion of colon cancer at 2.2% concentration.
